ABSTRACT
BACKGROUND: In eyes with diabetic macular edema, the relative efficacy of administering aflibercept monotherapy as compared with bevacizumab first with a switch to aflibercept if the eye condition does not improve sufficiently (a form of step therapy) is unclear. METHODS: At 54 clinical sites, we randomly assigned eyes in adults who had diabetic macular edema involving the macular center and a visual-acuity letter score of 24 to 69 (on a scale from 0 to 100, with higher scores indicating better visual acuity; Snellen equivalent, 20/320 to 20/50) to receive either 2.0 mg of intravitreous aflibercept or 1.25 mg of intravitreous bevacizumab. The drug was administered at randomization and thereafter according to the prespecified retreatment protocol. Beginning at 12 weeks, eyes in the bevacizumab-first group were switched to aflibercept therapy if protocol-specified criteria were met. The primary outcome was the mean change in visual acuity over the 2-year trial period. Retinal central subfield thickness and visual acuity at 2 years and safety were also assessed. RESULTS: A total of 312 eyes (in 270 adults) underwent randomization; 158 eyes were assigned to receive aflibercept monotherapy and 154 to receive bevacizumab first. Over the 2-year period, 70% of the eyes in the bevacizumab-first group were switched to aflibercept therapy. The mean improvement in visual acuity was 15.0 letters in the aflibercept-monotherapy group and 14.0 letters in the bevacizumab-first group (adjusted difference, 0.8 letters; 95% confidence interval, -0.9 to 2.5; P = 0.37). At 2 years, the mean changes in visual acuity and retinal central subfield thickness were similar in the two groups. Serious adverse events (in 52% of the patients in the aflibercept-monotherapy group and in 36% of those in the bevacizumab-first group) and hospitalizations for adverse events (in 48% and 32%, respectively) were more common in the aflibercept-monotherapy group. CONCLUSIONS: In this trial of treatment of moderate vision loss due to diabetic macular edema involving the center of the macula, we found no evidence of a significant difference in visual outcomes over a 2-year period between aflibercept monotherapy and treatment with bevacizumab first with a switch to aflibercept in the case of suboptimal response. (Funded by the National Institutes of Health; Protocol AC ClinicalTrials.gov number, NCT03321513.).
Subject(s)
Angiogenesis Inhibitors , Bevacizumab , Diabetic Retinopathy , Macular Edema , Receptors, Vascular Endothelial Growth Factor , Recombinant Fusion Proteins , Adult , Angiogenesis Inhibitors/administration & dosage , Angiogenesis Inhibitors/adverse effects , Angiogenesis Inhibitors/therapeutic use , Bevacizumab/administration & dosage , Bevacizumab/adverse effects , Bevacizumab/therapeutic use , Diabetes Mellitus/drug therapy , Diabetic Retinopathy/complications , Diabetic Retinopathy/drug therapy , Humans , Intravitreal Injections , Macular Edema/drug therapy , Macular Edema/etiology , Ranibizumab/adverse effects , Receptors, Vascular Endothelial Growth Factor/administration & dosage , Receptors, Vascular Endothelial Growth Factor/therapeutic use , Recombinant Fusion Proteins/administration & dosage , Recombinant Fusion Proteins/adverse effects , Recombinant Fusion Proteins/therapeutic use , Vascular Endothelial Growth Factor ASubject(s)
Biopsy/methods , Giant Cell Arteritis/pathology , Temporal Arteries/pathology , Aged , Aged, 80 and over , Biopsy/adverse effects , Biopsy/standards , Facial Nerve Injuries/etiology , Female , Humans , Male , Middle Aged , Predictive Value of Tests , Retrospective Studies , Risk Assessment , Risk FactorsSubject(s)
Epiretinal Membrane/genetics , Intramolecular Oxidoreductases/genetics , Macrophage Migration-Inhibitory Factors/genetics , Polymorphism, Single Nucleotide/genetics , Promoter Regions, Genetic/genetics , Retinal Detachment/genetics , Vitreoretinopathy, Proliferative/genetics , Adult , Aged , Aged, 80 and over , Epiretinal Membrane/pathology , Female , Genotyping Techniques , Humans , Male , Middle Aged , Polymerase Chain Reaction , Retinal Detachment/pathology , United States , Vitreoretinopathy, Proliferative/pathology , Young AdultABSTRACT
A 64-year-old man with type 2 diabetes mellitus and plaque psoriasis presented to the emergency room with 3 days of progressive right eye pain and decreased vision. After extensive workup and multidisciplinary team effort, the patient was diagnosed with and treated for unilateral endogenous methicillin-sensitive Staphylococcus aureus endophthalmitis, bacteraemia and osteomyelitis of the foot. The patient had been started on the interleukin 17 (IL-17) inhibitor secukinumab for his treatment-resistant plaque psoriasis 4 weeks prior to presentation. After treatment, his final vision was light perception and the foot infection resolved without sequelae. To our knowledge, this is the first reported case of both endogenous endophthalmitis and osteomyelitis associated with an IL-17 inhibitor.
Subject(s)
Antibodies, Monoclonal/adverse effects , Diabetes Mellitus, Type 2/complications , Endophthalmitis/etiology , Immunologic Factors/adverse effects , Interleukin-17/antagonists & inhibitors , Osteomyelitis/etiology , Psoriasis/drug therapy , Anti-Bacterial Agents/therapeutic use , Antibodies, Monoclonal/therapeutic use , Antibodies, Monoclonal, Humanized , Bacteremia/complications , Bacteremia/microbiology , Diabetes Complications , Endophthalmitis/drug therapy , Endophthalmitis/microbiology , Eye/pathology , Eye Infections, Bacterial/complications , Eye Infections, Bacterial/microbiology , Humans , Immunologic Factors/therapeutic use , Male , Methicillin-Resistant Staphylococcus aureus , Middle Aged , Osteomyelitis/drug therapy , Osteomyelitis/microbiology , Pain/etiology , Staphylococcal Infections/complications , Staphylococcal Infections/microbiology , Vision, Low/etiologyABSTRACT
The indigenous populations of the South Pacific experience a high burden of rheumatic heart disease (RHD). Here we report a genome-wide association study (GWAS) of RHD susceptibility in 2,852 individuals recruited in eight Oceanian countries. Stratifying by ancestry, we analysed genotyped and imputed variants in Melanesians (607 cases and 1,229 controls) before follow-up of suggestive loci in three further ancestral groups: Polynesians, South Asians and Mixed or other populations (totalling 399 cases and 617 controls). We identify a novel susceptibility signal in the immunoglobulin heavy chain (IGH) locus centring on a haplotype of nonsynonymous variants in the IGHV4-61 gene segment corresponding to the IGHV4-61*02 allele. We show each copy of IGHV4-61*02 is associated with a 1.4-fold increase in the risk of RHD (odds ratio 1.43, 95% confidence intervals 1.27-1.61, P=4.1 × 10-9). These findings provide new insight into the role of germline variation in the IGH locus in disease susceptibility.
Subject(s)
Alleles , Genetic Predisposition to Disease , Immunoglobulin Heavy Chains/genetics , Rheumatic Heart Disease/genetics , Adult , Asian People , Case-Control Studies , Child , Female , Gene Expression , Genome-Wide Association Study , Haplotypes , Humans , Immunoglobulin Heavy Chains/immunology , Male , Native Hawaiian or Other Pacific Islander , Oceania , Odds Ratio , Rheumatic Heart Disease/ethnology , Rheumatic Heart Disease/immunology , Rheumatic Heart Disease/pathology , RiskABSTRACT
Feral swine are globally known as one of the most destructive invasive vertebrates, damaging native habitats, native plants and animals, agriculture, infrastructure, spreading diseases. There has been little quantification on their disturbance to archaeological sites across a broad landscape. Over 6 years we inspected 293 significant archaeological sites for swine disturbance across a vast area. We found a 42% prevalence of swine disturbance among all sites, with prevalence not distinguishable among prehistoric sites, historic sites, and sites with both components. The areas of disturbance mapped within three historic homestead sites showed 5-26% of total site surface area rooted. Disturbance was not evident upon re-inspection of one of these sites after 18 months, indicating how evidence of disturbance can be obscured in this environment. Thus, our observed 42% prevalence of disturbance should be considered a minimum for disturbance occurring through time. Artifacts depths were <10 cm of the surface at 85% of the sites and <20 cm of the surface for 90% of the sites. Feral swine rooting commonly exceeds 20 cm in depth, especially in soft sandy substrates typical of Florida, making the great majority of the studied sites highly vulnerable to artifact damage or displacement.